This study looks at how well a medicine called Mirikizumab works in children with moderate to severe ulcerative colitis (UC). UC is a condition where the large intestine gets swollen and has sores. The study will also see how the body handles the medicine and check for any side effects. Children who finish the study can join a longer follow-up study.
- This study is for boys and girls aged 2 to 18 years, weighing more than 10 kg (about 22 pounds).
- Participants need to have tried other treatments without success and have UC for at least 3 months.
- Children with other digestive diseases, immune issues, or certain surgeries cannot join.
Key Points to Consider:
- Participation might require several visits and tests.
- Joining the follow-up study is optional after completing this one.
- Discuss potential side effects and benefits with doctors before joining.